The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients

Basit Öğe Kaydı
dc.authoridBOSTANCI, COSKUN/0000-0002-4493-8653
dc.contributor.authorBostanci, C.
dc.contributor.authorDemir, D. O.
dc.date.accessioned2024-09-29T15:54:54Z
dc.date.available2024-09-29T15:54:54Z
dc.date.issued2024
dc.departmentKarabük Üniversitesien_US
dc.description.abstractObjective: To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients. Methods: 191 patients with PSA levels between 4 -10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of <0.15 ng/mL/mL, f/t PSA ratio of >0.15, and a combination of both. Patients were divided into three groups according to these two parameters, which were PSAD 0.01 -0.07 ng/mL/mL and PSA ratio >= 25 in a low-risk group, PSAD 0.08 -0.15 ng/mL/mL, and f/t PSA ratio 0.15 -0.24 an intermediate-risk group and high -risk group, in which PSAD > 0.15 ng/mL/mL and f/t ratio <15. Results: NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high -risk group. NPV of negative mpMRI results were so close when combined with PSAD < 0.15 ng/mL/mL f/t PSA > 15. Conclusion: f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. advise not to avoid prostate biopsy when PSAD is >0.15 ng/mL/mL and the f/t PSA ratio <0.15. However, we need randomized controlled studies with more patients to confirm study. (c) 2023 AEU. Published by Elsevier Espan a, S.L.U. All rights reserved.en_US
dc.identifier.doi10.1016/j.acuroe.2023.10.004
dc.identifier.endpage245en_US
dc.identifier.issn0210-4806
dc.identifier.issn1699-7980
dc.identifier.issue3en_US
dc.identifier.pmid37838326en_US
dc.identifier.startpage238en_US
dc.identifier.urihttps://doi.org/10.1016/j.acuroe.2023.10.004
dc.identifier.urihttps://hdl.handle.net/20.500.14619/4349
dc.identifier.volume48en_US
dc.identifier.wosWOS:001220627500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Espanaen_US
dc.relation.ispartofActas Urologicas Espanolasen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFree/total prostate-specific antigen ratioen_US
dc.subjectProstate specific antigen densityen_US
dc.subjectMultiparametric prostate magnetic resonance imaginen_US
dc.titleThe effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu